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Mac rages produce various arachidonic acid (AA) metabolites which may either 
enhance or suppress inflammatory processes. We investigated AA metabolite produc- 
tion by alveolar macrophages (AMs) from 11 patients with pulmonary sarcoidosis and 9 
normal volunteers. We assessed the production of both cyclooxygenase products (pros- 
taglandin (PC) E,, thromboxane B, (TXB,), PGF,,, and 6-keto-PGF,,) and lipoxygenase 
products (leukotrienes (LT) and hydroxyeicosatetraenoic acids (HETEs)) in AM cul- 
tures. We found that sarcoid AMs produced less PGE,, TXB,, 6-keto-PGF,,, and 
HETEs in both the unstimulated and the calcium ionophore-stimulated states compared 
with normal AMs. Sarcoid AMs also produced less PGF,, and LTs in the unstimulated 
state after 1 hr of incubation, but following calcium ionophore stimulation, these 
differences did not achieve statistical significance. We conclude that sarcoid AMs 
have a reduced capacity to produce AA metabolites compared with that of nor- 
mal AMs. 8~ 1987 Academic Prers. Inc. 
INTRODUCTION 
Metabolites of arachidonic acid (AA) are important regulatory molecules which 
influence the intensity and duration of inflammatory processes (1,2). Arachidonic 
acid may be metabolized by both the cyclooxygenase (CO) pathway, yielding 
prostaglandins (PGs) and thromboxanes, and the lipoxygenase (LO) pathway, 
producing leukotrienes and hydroxyeicosatetraenoic acids (HETEs) (2-4). 
Products of both pathways possess potent and diverse immunoregulatory effects 
(2-5). PGE, and PGI, have predominantly antiinflammatory effects, while 
PGF,,, thromboxane A,, and most LO products may potentiate inflammation 
(2-4, 6). Hence, the relative concentrations of specific AA metabolites may influ- 
ence the direction of an inflammatory reaction, either to amplification or to reso- 
lution. Prostaglandins of the E series exert predominantly immunosuppressive 
effects and may function as important modulators of cellular immune responses 
(5, 7, 8). Both exogenous administration of E series PGs and endogenous produc- 
tion of PGE, by mononuclear phagocytes have been shown to suppress several 
important lymphocyte and macrophage (MO) functions. PGE, inhibits T-cell pro- 
liferation (3) and natural killer cell activity (3), induces the expression of T sup- 
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pressor cell phenotype (9), reduces Ia and HLA-DR antigen expression by im- 
mune effector cells (6), and inhibits monokine release (10). The role of lipoxy- 
genase products in the expression and modulation of inflammatory processes is 
less clear. However, certain LO products are potent chemotactic agents, stimu- 
late cellular aggregation and degranulation, and stimulate T-cell mitogenesis and 
monokine release (2, 4, 11). thereby promoting inflammation. Macrophages are 
important sources of AA metabolites compared with other immune effector cells, 
as they are unusually rich in arachidonic acid and possess the ability to metabo- 
lize AA by either pathway (1, 2, 12). Although many factors determine the 
amount and types of AA metabolites produced, the activation state of the macro- 
phage has special importance (2, 12-14). Several investigators have demon- 
strated that chemically elicited or immunologically activated M@s produce less 
AA metabolites than resident M@s (2, 12-14). Further, the amount and type of 
AA metabolites may change with evolution of inflammatory processes and are 
subject to immunomodulatory influences. For example, M@s isolated from mu- 
rine hypersensitivity lung granulomas demonstrate an initial increase in the quan- 
tities and complexity of AA metabolites as the acute granulomatous process de- 
velops (2, 15), but release lesser amounts of PGs and exhibit decreased ability to 
metabolize AA in later phases of granuloma formation (15). Whether similar 
changes in AA metabolism occur in chronic granulomatous diseases in man has 
not, to our knowledge, been investigated. Since pulmonary sarcoidosis is a granu- 
lomatous disorder in which interactions between activated alveolar macrophages 
and T lymphocytes are important in the pathogenesis (16-18). we investigated 
arachidonate metabolism by AMs isolated by bronchoalveolar lavage from pa- 
tients with sarcoidosis and normal controls. We demonstrated a decreased pro- 
duction of cyclooxygenase and lipoxygenase products by sarcoid AMs, sug- 
gesting down-regulation. Hence, changes in AA metabolites produced by macro- 
phages may influence the direction and extent of granulomatous responses. 
MATERIALS AND METHODS 
Patient population. Bronchoalveolar lavage (BAL), utilizing the flexible fiber- 
optic bronchoscope, was performed in 11 nonsmoking patients with sarcoidosis 
as part of the initial diagnostic evaluation of an abnormal chest roentgenogram. 
Transbronchial lung biopsy demonstrated noncaseating granulomas in all cases, 
and other granulomatous diseases were reliably excluded. Two sarcoid patients 
were roentgenographic stage 1, eight were stage II, and one was stage III. Pulmo- 
nary function tests were normal in six and showed a restrictive defect in five. As 
a group, the patients with sarcoidosis had the following pulmonary function ab- 
normalities (mean as a percentage of predicted ? standard deviation): forced 
vital capacity (FVC) 77.2 +- 1.5. I%, total lung capacity (TLC) 79.5 2 9.5%, and 
single breath diffusing capacity (D,CO) 80.4 i 12.2%. Six of 11 patients had 
symptoms of cough or dyspnea attributable to pulmonary sarcoidosis. Based on 
clinical criteria, five of the symptomatic patients were judged to have active dis- 
ease and were subsequently treated with corticosteroids. The remaining patients 
were considered to have clinically inactive disease and were not treated. No pa- 
tient was receiving steroids, immunosuppressive agents, or nonsteroidal antiin- 
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flammatory agents at the time of BAL. Although CO metabolic products were 
assessed in all 11 patients, LO metabolism was evaluated in only the last five 
patients in the study. Two of these five were symptomatic, had mild restrictive 
defects on pulmonary function tests, and were judged to have clinically active 
disease. The remaining three sarcoid patients were asymptomatic, had normal 
pulmonary function, and were considered to have clinically inactive disease. 
There were no significant clinical, roentgenographic, or physiological differences 
between these five sarcoid patients who had LO products determined compared 
with the remaining six sarcoid patients or the group as a whole. Nine normal 
nonsmoking volunteers were recruited as control subjects. All were asymptom- 
atic and had normal chest roentgenograms and pulmonary function tests. None 
was receiving medication at the time of BAL. None of the patients or normal 
volunteers had signs of an infectious process within 6 weeks of the time of BAL. 
Technique of bronchoalveolar lavage. Bronchoalveolar lavage was performed 
using standard methods (16- 19). After premeditation with intramuscular atro- 
pine and codeine, topical anesthesia was achieved with nebulized 4% lidocaine to 
the oropharynx and 2% lidocaine to the trachea and bronchi. Following brief vi- 
sual inspection of the airways, the tip of the bronchoscope was gently wedged 
into a subsegmental bronchus of the right middle lobe or lingula, and 30-ml ali- 
quots of sterile normal saline were instilled via the suction channel of the bron- 
choscope and immediately aspirated into a sterile collection chamber. This pro- 
cess was repeated for a total instillation of 240 ml. Of the instilled fluid, 50 to 75% 
was usually recovered. 
Preparation of AM suspension. Recovered BAL fluid was filtered and centri- 
fuged at 4OOg, and the pellet was resuspended in sterile RPM1 1640 (Grand Island 
Biological Co., Grand Island, N.Y.). Total cell count was performed using a hema- 
cytometer. A cell differential was obtained by counting 500 cells on slides stained 
with Papanicolaou’s stain. The cell suspension was then washed three times and 
resuspended to a final concentration of 1 x lo6 cells/ml in sterile RPM1 1640 with 
10% fetal calf serum (K. C. Biological, Lenexa, Kan.) and 20 mcg/ml of genta- 
micin (complete media). 
Assays for cyclooxygenase products. One milliliter of the cell suspension was 
added to 35mm plastic tissue culture plates (Corning Glass Works, Corning, 
N.Y.) and was incubated at 37°C in 5% CO,/95% air for 4 hr. The plates were 
rinsed twice vigorously to remove nonadherent cells, and 1.5 ml of RPM1 1640 
with 30 mcg of gentamicin (serum-free media) was added to each plate. The plates 
were incubated for an additional 16 hr, and the supernatants were collected and 
frozen at -20°C. The adherent cells were washed with warm RPM1 twice, and 
I .S ml of serum free media was added to each plate. Half of the plates received 
calcium ionophore A23187 in a final concentration of 1O-5 M. After 1 hr of incu- 
bation at 37°C in 5% CO,/95% air, the supernatants were collected and frozen. 
Viability of the adherent cells as determined by trypan blue exclusion was greater 
than 90% in all cases. The number of adherent cells was quantitated by direct 
counting of monolayers stained with Wright’s stain. The adherent cells were rou- 
tinely >95% macrophages based on nuclear morphological criteria, phagocytosis 
of inert latex beads, and positive staining for nonspecific esterase. Supernatants 
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were assayed for PGE,, PGF,,, thromboxane B,, and 6-keto-PGF,, using radio- 
immunoassays as described by Fitzpatrick and co-workers (20, 21). Briefly, pro- 
tein and free fatty acids were extracted from the samples prior to the addition of 
antibodies. Bound and free ligand were separated using dextran-coated charcoal. 
All assays were run in duplicate. 
Assays for lipoxygermse products. To evaluate lipoxygenase pathway metabo- 
lism, alveolar macrophage suspensions from five of the normals and five of the 
sarcoid patients were obtained by methods described above. Two milliliters of the 
cell suspension was applied to each 60-mm tissue culture plate (Lab-Tek, Miles 
Laboratories). After 4 hr of incubation at 37°C in 5% CO,/95% air, nonadherent 
cells were removed, and 2 ml of serum-free media containing 1 $Zi of [3H]AA (91 
Ci/mmol sp act; New England Nuclear, Boston Mass.) was added to each plate. 
Following an additional 16 hr of incubation, the plates were washed with warm 
RPM1 to remove unincorporated radiolabel. Two milliliters serum-free media was 
then added to each dish, with half of the plates receiving IOd5 M A23187. After a 
1 hr incubation, the dishes were scraped to resuspend the adherent macrophages, 
and AA metabolites were extracted as follows. The cell-containing media were 
collected and acidified to pH 3 with IN HCI, then extracted twice with 3 vol of 
ethyl acetate. The solvent was evaporated using a Speed Vat concentrator (Sa- 
vant Instruments, Hicksville, N.Y.). Extracts were stored under 100% N, at 
-2o”C, then were dissolved in 0.1 ml absolute methanol just prior to column 
chromatography. Metabolites of AA were identified by reverse-phase high perfor- 
mance liquid chromatography (HPLC) using a modified method of Van Rollins et 
al. (22). One-tenth-milliliter samples were applied to 5 km C-18 reverse phase (30 
x 0.4 cm) column (Varian Associates, Palo Alto, Calif.) at 29°C with a I mlimin 
flow rate. The solvent system containing acetonitrile (Burdick and Jackson Labo- 
ratories, Muskegon, Mich.)/water/trifluoroacetic acid (Pierce Chemical Co., 
Rockford, 111.) was used as described previously (23). The eluate was contin- 
uously monitored for ultraviolet absorbance and radioactivity (23). The column 
was calibrated using radiolabeled and unlabeled known standards. Unlabeled leu- 
kotrienes (LTs) were kindly provided by Dr. J. Rokach (Merck Frost Laborato- 
ries, Quebec, Canada), and 5- and 12-HETE were kindly provided by Dr. J. Pike 
and Dr. Robert Gorman (Upjohn Co., Kalamazoo, Mich.). 14C-labeled LTB, was 
provided by Henry Showell (Pfizer Central Research, Groton, Conn.). [3H]LTC4 
and [3H]AA were purchased from New England Nuclear. 
For purposes of data analysis, the elution peaks corresponding to LTB, and 
LTC, and the peaks corresponding to 5-HETE, I2-HETE, and I5-HETE were 
pooled, respectively, for quantitation of leukotrienes and monohydroxyeicosa- 
tetraenoic acids (mono-HETEs). 
Statistical analysis. Statistical analysis was performed using the unpaired Stu- 
dent’s t test. P values of less than 0.05 were considered significant. Data are 
expressed as means ? standard error of the means. 
RESULTS 
Total Cell and Differential Counts of BAL 
Bronchoalveolar lavage in the normals revealed a mean cell count of 16.5 + 2. I 
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million which comprised a mean of 9.8 + 2.0% lymphocytes, 88.4 + 2.0% al- 
veolar macrophages, and 1.8 + 0.6% neutrophils. These data are comparable 
with results published in normals by other investigators (I 1, 13, 36). The mean 
BAL count in the I1 sarcoid patients (34.4 k 5.4 million) was significantly greater 
compared with that of normal volunteers (P < 0.005). Mean percentage lympho- 
cytes on BAL differential count also was significantly greater in the sarcoid pa- 
tients (mean 3 1.9 + 4.0%) when compared with that of normal volunteers (P < 
0.001). Mean percentage BAL polymorphonuclear leukocytes in the sarcoid pa- 
tients (0.8 -+ 0.3) was not significantly different compared with that in the normal 
volunteers (P > 0.2). 
Cyclooxygenase Products 
Sarcoid AMs produced less CO metabolites than AMs from normal volunteers 
both in the resting and ionophore-stimulated states. Following 1 hr incubation, 
sarcoid AMs produced less PGE, compared with normals both in the resting state 
(P < 0.01) and following stimulation by calcium ionophore (P < 0.001; Fig. 1). 
After 16 hr of incubation, unstimulated sarcoid AMs produced less PGE, than did 
unstimulated normal AMs (P < 0.001) as shown in Fig. 2. 
Sarcoid AMs also produced less thromboxane B, after 1 hr incubation in both 
the resting and ionophore-stimulated state compared with normal AMs (P < 0.01; 
Fig. I). After 16 hr of incubation, unstimulated sarcoid AMs produced threefold 
less thromboxane B, than did normal AMs (P < 0.05; Fig. 2). 
Sarcoid AMs produced significantly less 6-keto-PGF,, after 1 hr in both the 
resting and ionophore-stimulated states compared with normal AMs (P < 0.005, 
both comparisons; Fig. 1). Unstimulated sarcoid AMs also produced less 6-keto- 
F,, following 16 hr incubation compared with normal AMs (P < 0.003; Fig. 2). 
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FIG. 1. Cyclooxygenase metabolite production by human alveolar macrophages after 1 hr of incu- 
bation with and without 1O-5 M A23187. Metabolite production is expressed as nanograms/million 
cells. * denotes statistical significance comparing normal and sarcoid AMs incubated under similar 
conditions. Compared with normal AMs, unstimulated sarcoid AMs produce significantly less PGE,, 
TXB,. PGF,, and 6-keto-PGF,,. With A23187 stimulation, sarcoid AMs produce less PGE,, TXB,, 
and 6-keto PGF,, compared with normal AMs. 
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FIG. 2. Cyclooxygenase metabolite production by human alveolar macrophages after 16 hr of incu- 
bation without exogenous stimuli. Metabolite production is expressed as nanograms/million cells. 
Compared with normal AMs, sarcoid AMs produce significantly less PGE>. TXB,, and 6-keto-PGF,,. 
Unstimulated sarcoid AMs produced significantly less PGF,, after 1 hr incuba- 
tion compared with normals (Fig. 1; P < 0.05). With calcium ionophore stimula- 
tion, differences between sarcoid and normal AMs at 1 hr did not achieve statis- 
tical significance. After 16 hr of incubation, PGF,, production did not differ sig- 
nificantly between unstimulated sarcoid and normal AMs (P > 0.10; Fig. 2). 
Lipoxygenase Products 
Unstimulated sarcoid AMs produced less LTs and less HETEs after 1 hr of 
incubation compared with normal AMs (P < 0.03 and P < 0.02, respectively; Fig. 
3). Following stimulation with calcium ionophore, sarcoid AMs produced less 
HETEs than did normal AMs, but there was no significant difference in LT pro- 
duction between sarcoid and normal AMs (Fig. 3). A representative HPLC pro- 
file is depicted in Fig. 4. 
Correlation of AA Metabolite Production and Clinical Activity 
There was no correlation between production of either CO or LO pathway 
metabolites and the clinical assessment of disease activity. Specifically, AA me- 
tabolite production did not correlate with symptoms, chest roentgenographic 
stage, pulmonary function testing, or BAL total cell count or lymphocyte count. 
DISCUSSION 
Pulmonary sarcoidosis is a disease in which interactions between activated 
lung T lymphocytes and mononuclear phagocytes appear to be responsible for the 
induction and evolution of the granulomatous inflammatory lesion (16-19, 24). 
The sarcoid granuloma is comprised predominantly of monocyte-macrophage- 
derived cells (epithelioid cells, multinucleated giant cells) within the central core, 
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FIG. 3. Lipoxygenase metabolite production by human alveolar macrophages after 1 hr of incuba- 
tion with and without A23187 stimulation. Leukotriene and HETE production is expressed as counts 
per minute/million cells. * denotes statistical significance comparing normal and sarcoid AMs incu- 
bated under similar conditions. Compared with normal AMs, unstimulated sarcoid AMs produce less 
leukotrienes and less HETEs. After A23187 stimulation, sarcoid AMs produce less HETEs than do 
normal AMs. 
surrounded by lymphocytes in the periphery (16, 17, 24). This granulomatous 
response, however, appears to be preceded by an alveolitis composed of acti- 
vated lymphocytes and mononuclear phagocytes (16, 17, 24). Increased numbers 
of alveolar macrophages (16, 17, 19), activated T cells (16- 18, 24), and T helper 
cells (17, 18), with decreased numbers of T suppressor cells (17, 18), have been 
demonstrated in BAL fluid in patients with active pulmonary sarcoidosis, indi- 
cating a heightened cellular immune response in the lung. Among these various 
immune effector cells, the alveolar macrophage represents a key cell in the for- 
mation of the sarcoid granuloma by virtue of its prominence in the histopathology 
TIME (mln) 
FIG. 4. A representative HPLC profile of LO metabolite production by human alveolar macro- 
phages from a patient with sarcoidosis. The elution peaks are identified by comparison with labeled 
known standards. 
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of the reaction, its ability to actively interact with T lymphocytes (16. 25). and its 
potency as a secretory cell (2, 26). Several features suggesting activation of the 
alveolar macrophage in sarcoidosis have been demonstrated. Sarcoid AMs ob- 
tained by BAL contain increased amounts of lysozyme and angiotensin-con- 
verting enzyme (27), have morphological features consistent with an activated 
state (16, 17, 27), display enhanced DR antigen expression (24) and antigen-pre- 
senting capacity (17). and spontaneously release monokines including inter- 
leukin-1 (28). alveolar macrophage-derived growth factor (29). and fibronectin 
(30). These MIZ) characteristics are capable of enhancing the inflammatory and 
fibrotic components of the sarcoid reaction. The factors responsible for limiting 
or regulating the granulomatous response, however, are poorly understood. In 
animal models of granulomatous inflammation, macrophages have been shown to 
produce endogenous mediators which may influence the course of chronic inflam- 
matory processes (1, 15). Of particular importance are the types and amounts of 
macrophage-derived arachidonate metabolites. Since M@s are capable of metab- 
olizing AA into both cyclooxygenase and lipoxygenase products (2, 12, 31), 
changes in the types and quantities of AA metabolites may modulate the extent 
and direction of inflammatory reactions (2, 15, 23, 32). Despite the potential im- 
portance of AA metabolites in influencing chronic granulomatous inflammation, 
data in humans are limited. 
In the present study. we demonstrated an altered ability of AMs from patients 
with pulmonary sarcoidosis to metabolize AA as compared with normal AMs. In 
addition, by utilizing both radioimmunoassays and HPLC. we have more fully 
characterized the spectrum of AA metabolites synthesized by normal and sarcoid 
AMs. In our system, the RIA detects products based on the metabolism of endog- 
enous stores of AA, while the HPLC detects products based on the metabolism 
of exogenous [3H]AA. Thus, it must be noted that a difference in the levels of 
metabolites may occur depending on the mobilization of endogenous or exoge- 
nous arachidonic acid pools. Whereas previous studies of AA metabolism by 
human AMs have analyzed either CO products (33) or LO products (34-37), we 
assessed products of both pathways in normal and sarcoid AMs to better delin- 
eate the entire AA metabolic profile. We demonstrated that PGE, and TXB, were 
the predominant CO metabolites produced by sarcoid and normal AMs, while 
smaller amounts of PGF,, and 6-keto-PGF,, were detected. This is consistent 
with previous investigations demonstrating that PGE, and TXB, were the major 
CO-derived metabolites synthesized by human AMs (33). We also demonstrated 
that stimulation with calcium ionophore significantly increased the production of 
CO metabolites by both normal and sarcoid AMs. Utilizing HPLC, we found that 
both normal and sarcoid AMs produced mono-HETEs as the predominant LO 
products, but smaller amounts of leukotrienes were also detected. Among the 
mono-HETEs, the largest peak coeluted with the 5-HETE standard, while other 
smaller peaks co-migrated with standards for 12- and I5-HETE. This is consistent 
with the work of previous investigators (34, 36, 37), all of whom reported that 
5-HETE was the predominant mono-HETE synthesized by human AMs. Our 
findings differ from those of Martin et al. (36) and Laviolette et al. (37), however, 
as these authors failed to detect either 12- or 15HETE. Chang and co-workers 
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demonstrated 12-HETE production by human AMs (34), consistent with our 
findings, but were unable to detect 15HETE synthesis. We also demonstrated 
that both normal and sarcoid AMs produced LTs, with the major peak coeluting 
with LTB,. This agrees with several other reports describing LTB, as the pre- 
dominant leukotriene produced by human AMs (35-37). Although most investi- 
gators have failed to detect LTC,, LTD,, and LTE, (35-37), LTD, has been de- 
scribed as a metabolic product of AA by human AMs (38). Although we failed to 
detect LTD,, we observed a small peak of material which coeluted with LTC,. 
thus indicating that normal and sarcoid AMs are capable of synthesizing small 
quantities of LTC,. 
Of particular interest in our study was the generalized reduction in AA metabo- 
lism demonstrated by sarcoid AMs compared with normal AMs. Substantial re- 
ductions in PGE,, TXB,, 6-keto-PGF,,, and mono-HETE production by sarcoid 
AMs were observed. Reductions in PGF,, and leukotriene release by sarcoid 
AMs also were demonstrated, but were smaller in magnitude. Our findings of 
reductions in both CO and LO metabolism by sarcoid AMs are consistent with 
down-regulation of AA metabolism previously demonstrated in chronically acti- 
vated macrophages in animals (2, 12, 39, 40). For example, striking reductions in 
PGE, synthesis have been demonstrated in murine peritoneal macrophages acti- 
vated by Corynebacterum parvum, Bacille-Calmette-Guerin (BCG), or carra- 
geenin-induced granulomas (13). Scott et al. ( 12) confirmed decreased production 
of PGE, as well as suppression of PGI,, HETEs, and LTC synthesis by C. 
parvum and BCG-activated M@s compared with resident Me)s. 
In addition to change in quantities of AA metabolites released by chronically 
activated M@s, the types of AA metabolic products may change as inflammatory 
processes evolve. For example, AA metabolites released by M@s isolated from 
Schistosoma egg-induced murine lung granulomas 4 days post-egg embolization 
are similar to the profile seen in resident peritoneal macrophages (32, 41). How- 
ever, M@s isolated at 8 and 16 days display altered arachidonate metabolism with 
a shift from production of IZHETE to both 5-HETE and 12-HETE. Additional 
changes in MQ) arachidonate metabolism can be demonstrated at 8 and 20 weeks. 
M@ isolated from 20-week granulomas release lesser amounts of PGs and exhibit 
reduced AA metabolism compared with the more acute (8-week), highly cellular 
granulomas (15). Hence, changes in the profile of AA metabolites released by 
MQ)s at sites of disease may be important in modifying the course of inflamma- 
tory processes. 
The mechanism by which this down-regulation of AA metabolism occurs re- 
mains unclear. Humes et al. noted a markedly decreased rate of AA release from 
elicited compared with resident murine PEMs, consistent with reduced phospho- 
lipase A, activity (13). Whether a similar mechanism is operative in human AMs 
is unknown, although Laviolette and co-workers suggested that reduced phos- 
pholipase activity could explain their findings of reduced CO metabolite produc- 
tion by human smoker AMs (33). Diminished phospholipase activity could also 
explain the reduced production of both CO and LO metabolites which we ob- 
served in sarcoid AMs, but this remains speculative as we did not specifically 
measure phospholipase activity. In experimental models, phospholipase activity 
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may be regulated by mediators released by immune effector cells. For example, 
y-interferon, a product of both lymphocytes and macrophages, suppresses phos- 
pholipase activity in murine PEMs in V~~YO, resulting in reduced release of AA 
(42). This modulating effect of y-interferon on phospholipase activity is particu- 
larly intriguing in light of Hunninghake er al.‘s recent report that AMs isolated 
from patients with active pulmonary sarcoidosis release increased amounts of 
y-interferon (43). Thus, in viva exposure of sarcoid AMs to y-interferon may ex- 
plain the down-regulation in AA metabolism observed in our experiments. 
The significant decrease in PGE, production by AMs from sarcoid patients is 
potentially very important since PGE, decreases lymphokine production (44) and 
lymphocyte mitogenesis (45) and suppresses a variety of monocyte and macro- 
phage functions (11, 46-48). Since PGE, is a potent suppressor of many inflam- 
matory events, reduced release of PGE, may intensify or perpetuate the height- 
ened cellular immunity evident in pulmonary sarcoid. Reduced levels of PGE, in 
the inflammatory environment could explain the observations of increased cyto- 
kine release, including that of y-interferon (43), interleukin-1 (28). and inter- 
leukin-2 (.52), and of increased HLA-DR antigen expression (25) and antigen pre- 
sentation capacity (17) previously reported in sarcoidosis. 
Since levels of PGE, and arachidonate metabolic products did not correlate 
with clinical, radiographic, or physiologic indicators of disease activity in our 
sarcoid patients, the significance of reduced AA metabolism in sarcoidosis is not 
clear. Additional studies. including serial assessments of sarcoid AM arachi- 
donate metabolism as the disease activity changes, are needed to clarify the role 
of altered AA metabolism in the pathogenesis of sarcoidosis. 
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